Gary K. Lee is CSO at Lyell Immunopharma, Inc. (LYEL). They have made 8 open-market trades across 1 company since 2025, most recently 2026-08-21.
CIK 0001907345
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LYEL | 16,220 | $132K |
Shares reported on the most recent Form 4, priced at the 2026-08-25 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LYEL | SELL | 2026-08-21 | 2026-08-25 | $15.54 | $23K | -8.1% | -34.2% | — |
| LYEL | SELL | 2026-08-10 | 2026-08-11 | $14.34 | $2K | +7.4% | -14.4% | — |
| LYEL | SELL | 2026-05-11 | 2026-06-15 | $18.92 | $2K | -8.2% | +11.1% | -12.4% |
| LYEL | SELL | 2026-02-11 | 2026-02-12 | $23.39 | $39K | -7.8% | -17.2% | -24.5% |
| LYEL | SELL | 2026-02-10 | 2026-02-11 | $23.12 | $3K | -5.5% | -13.0% | -21.2% |
| LYEL | SELL | 2025-11-10 | 2025-11-12 | $16.16 | $2K | +33.6% | +102.7% | +39.5% |
| LYEL | SELL | 2025-08-21 | 2025-08-22 | $10.54 | $15K | +8.9% | +22.4% | +62.0% |
| LYEL | SELL | 2025-08-11 | 2025-08-13 | $10.43 | $3K | +4.3% | +21.9% | +64.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.